Cargando…
2118. Patient Characteristics and Clinical Outcomes of Leptotrichia spp. Bacteremia
BACKGROUND: Leptotrichia spp. are anaerobic, gram-negative bacilli that are part of the normal oral and intestinal microbiota. Although traditionally considered non-pathogenic, these bacteria can result in invasive infections including bacteremia in immunosuppressed patients, particularly those with...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752598/ http://dx.doi.org/10.1093/ofid/ofac492.1739 |
_version_ | 1784850765816266752 |
---|---|
author | Ranganath, Nischal Challener, Douglas Schuetz, Audrey Stevens, Ryan W Shirley, Joshua D Shah, Aditya |
author_facet | Ranganath, Nischal Challener, Douglas Schuetz, Audrey Stevens, Ryan W Shirley, Joshua D Shah, Aditya |
author_sort | Ranganath, Nischal |
collection | PubMed |
description | BACKGROUND: Leptotrichia spp. are anaerobic, gram-negative bacilli that are part of the normal oral and intestinal microbiota. Although traditionally considered non-pathogenic, these bacteria can result in invasive infections including bacteremia in immunosuppressed patients, particularly those with neutropenia. There are limited published data to inform best management strategies in those with Leptotrichia bacteremia. METHODS: All cases of Leptotrichia spp. bacteremia between January 2012 and 2022 at our tertiary academic medical center were retrospectively reviewed to determine patient risk factors, clinical outcomes, and antimicrobial susceptibilities. Descriptive statistical methods were used. Antimicrobial susceptibilities were performed by agar dilution. RESULTS: 26 cases of Leptotrichia spp. bacteremia were identified (Figure 1). The mean patient age was 55 years (SD 17), with 9 female patients (35%). All 26 patients were immunocompromised, predominantly due to hematologic malignancy (69%) or hematopoietic stem cell transplant (23%) (HSCT). 25 of 26 patients were actively neutropenic, with a median duration of neutropenia of 21 days (13-26) (Table 1). The most frequent sources of Leptotrichia bacteremia were gastrointestinal translocation (60%), followed by catheter-related infection (35%). 10 patients had polymicrobial bacteremia (38.5%). The primary antibiotics utilized to treat Leptotrichia bacteremia included metronidazole (42%), piperacillin-tazobactam (27%), and carbapenems (19%). Overall, the mean duration of treatment was 11 days, with a 60-day all-cause mortality of 19% (Table 1) with no cases of microbiologic relapse. In the 22 clinical isolates evaluated for susceptibility, Leptotrichia spp. were largely susceptible to metronidazole, penicillin, ertapenem, and piperacillin-tazobactam, but uniformly resistant to moxifloxacin (Table 2). [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: Leptotrichia spp. may be a rare cause of bacteremia in neutropenic hosts, particularly those with underlying hematologic malignancies and HSCT. The pathogen has a favorable susceptibility profile to penicillins and carbapenems, but has high degree of resistance to fluoroquinolones. DISCLOSURES: All Authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-9752598 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-97525982022-12-16 2118. Patient Characteristics and Clinical Outcomes of Leptotrichia spp. Bacteremia Ranganath, Nischal Challener, Douglas Schuetz, Audrey Stevens, Ryan W Shirley, Joshua D Shah, Aditya Open Forum Infect Dis Abstracts BACKGROUND: Leptotrichia spp. are anaerobic, gram-negative bacilli that are part of the normal oral and intestinal microbiota. Although traditionally considered non-pathogenic, these bacteria can result in invasive infections including bacteremia in immunosuppressed patients, particularly those with neutropenia. There are limited published data to inform best management strategies in those with Leptotrichia bacteremia. METHODS: All cases of Leptotrichia spp. bacteremia between January 2012 and 2022 at our tertiary academic medical center were retrospectively reviewed to determine patient risk factors, clinical outcomes, and antimicrobial susceptibilities. Descriptive statistical methods were used. Antimicrobial susceptibilities were performed by agar dilution. RESULTS: 26 cases of Leptotrichia spp. bacteremia were identified (Figure 1). The mean patient age was 55 years (SD 17), with 9 female patients (35%). All 26 patients were immunocompromised, predominantly due to hematologic malignancy (69%) or hematopoietic stem cell transplant (23%) (HSCT). 25 of 26 patients were actively neutropenic, with a median duration of neutropenia of 21 days (13-26) (Table 1). The most frequent sources of Leptotrichia bacteremia were gastrointestinal translocation (60%), followed by catheter-related infection (35%). 10 patients had polymicrobial bacteremia (38.5%). The primary antibiotics utilized to treat Leptotrichia bacteremia included metronidazole (42%), piperacillin-tazobactam (27%), and carbapenems (19%). Overall, the mean duration of treatment was 11 days, with a 60-day all-cause mortality of 19% (Table 1) with no cases of microbiologic relapse. In the 22 clinical isolates evaluated for susceptibility, Leptotrichia spp. were largely susceptible to metronidazole, penicillin, ertapenem, and piperacillin-tazobactam, but uniformly resistant to moxifloxacin (Table 2). [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: Leptotrichia spp. may be a rare cause of bacteremia in neutropenic hosts, particularly those with underlying hematologic malignancies and HSCT. The pathogen has a favorable susceptibility profile to penicillins and carbapenems, but has high degree of resistance to fluoroquinolones. DISCLOSURES: All Authors: No reported disclosures. Oxford University Press 2022-12-15 /pmc/articles/PMC9752598/ http://dx.doi.org/10.1093/ofid/ofac492.1739 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstracts Ranganath, Nischal Challener, Douglas Schuetz, Audrey Stevens, Ryan W Shirley, Joshua D Shah, Aditya 2118. Patient Characteristics and Clinical Outcomes of Leptotrichia spp. Bacteremia |
title | 2118. Patient Characteristics and Clinical Outcomes of Leptotrichia spp. Bacteremia |
title_full | 2118. Patient Characteristics and Clinical Outcomes of Leptotrichia spp. Bacteremia |
title_fullStr | 2118. Patient Characteristics and Clinical Outcomes of Leptotrichia spp. Bacteremia |
title_full_unstemmed | 2118. Patient Characteristics and Clinical Outcomes of Leptotrichia spp. Bacteremia |
title_short | 2118. Patient Characteristics and Clinical Outcomes of Leptotrichia spp. Bacteremia |
title_sort | 2118. patient characteristics and clinical outcomes of leptotrichia spp. bacteremia |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752598/ http://dx.doi.org/10.1093/ofid/ofac492.1739 |
work_keys_str_mv | AT ranganathnischal 2118patientcharacteristicsandclinicaloutcomesofleptotrichiasppbacteremia AT challenerdouglas 2118patientcharacteristicsandclinicaloutcomesofleptotrichiasppbacteremia AT schuetzaudrey 2118patientcharacteristicsandclinicaloutcomesofleptotrichiasppbacteremia AT stevensryanw 2118patientcharacteristicsandclinicaloutcomesofleptotrichiasppbacteremia AT shirleyjoshuad 2118patientcharacteristicsandclinicaloutcomesofleptotrichiasppbacteremia AT shahaditya 2118patientcharacteristicsandclinicaloutcomesofleptotrichiasppbacteremia |